Compare BridgeBio Pharma Inc (BBIO) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Icl Group Ltd — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Icl Group Ltd trades at $5.3 (market cap $6.94B). The key difference: BridgeBio Pharma Inc is far larger — about 2.4× Icl Group Ltd's market cap, and Icl Group Ltd pays a 3.86% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | ICL | |
|---|---|---|
Market Cap | $16.61B | $6.94B |
Sector | Health | Basic Materials |
52-Week High | $90.17 | $6.84 |
52-Week Low | $47.29 | $4.80 |
Enterprise Value | $18.16B | $9.57B |
Dividend Yield | — | 3.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
ICL trades at $5.31, up 0.76% today, with a bullish technical signal from moving averages and strong Q2 2026 earnings beats. The company reported $7.15B revenue in 2025, with net income of $226M, and maintains a P/E of 22.13 and P/S of 0.89. Recent news highlights Q2 sales growth driven by potash and bromine prices, alongside a cost-transformation program.
Outlook is mixed: earnings momentum and dividend payments offer support, but declining profit margins and 100% hold analyst consensus indicate caution. Key risks include raw material cost volatility and geopolitical factors affecting the specialty minerals market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
